Galderma has announced that in a one-year, open-label, non-comparative study, Mirvaso (brimonidine) topical gel was demonstrated to be safe and effective when used once daily for up to 12 months.

Mirvaso is indicated for the persistent facial erythema of rosacea in adults >18 years old. Mirvaso works by constricting dilated facial blood vessels to reduce redness associated with rosacea. The study findings were published in the January issue of Journal of Drugs in Dermatology.

RELATED: Dermatological Disorders Resource Center

In the long-term study of 276 patients conducted at 27 centers in the U.S., patients with moderate-to-severe erythema of rosacea topically applied Mirvaso once daily for up to 12 months. During this time, the intensity of the erythema and any adverse events were noted. Other rosacea therapies (oral and topical) could also be used by the study patients.  Mirvaso was shown to be effective in reducing persistent facial erythema of rosacea from the first day of treatment and throughout the 12-month study.

No new major safety findings emerged from this study compared to the vehicle-controlled pivotal studies.

For more information call (817) 961-5000 or visit